Guidant Defibrillator Problems Result in $30M Settlement with DOJ

|

Boston Scientific has agreed to pay $30 million to settle government claims that its Guidant subsidiary knowingly sold defective heart implants to patients.  

The settlement was announced last week in a press release issued by the U.S. Department of Justice.

Guidant sold defective implantable defibrillators to hospitals between 2002 and 2005, and received Medicare payments from the federal government for the faulty heart implants, which is considered Medicare fraud, according to charges brought by the Justice Department.

Sports-Betting-Addiction-Lawsuits
Sports-Betting-Addiction-Lawsuits

Boston Scientific did not acquire Guidant until 2006, so while Boston Scientific itself had no part in the allegedly illegal activities, it assumed responsibility for the prior actions of the subsidiary when it purchased the company.

The implants in question were the Prizm 2 and the Renewal 1 and 2. According to the Justice Department, Guidant knew as early as 2002 that the devices were defective due to a problem known as arcing, where the electrical shock sent to the heart to maintain its rhythm comes back into the device, causing it to short circuit and rendering it inoperable. However, the company continued selling the devices for three years after it learned of the problem, federal investigators claim.

“Medicare patients who depend on cardiac defibrillators should not have to worry about whether their devices will work when they are needed,” Stuart F. Delery, Assistant Attorney General for the Justice Department’s Civil Division, said in the press release. “This settlement, along with the prior criminal prosecution of Guidant, demonstrates that there will be significant consequences when companies engage in conduct that threatens health and safety and violates the law.”

The Guidant heart device Medicare fraud lawsuit was filed by the Justice Department in January 2011. The complaint came after a federal judge accepted a guilty plea and a $296 million settlement from Guidant regarding claims that it tried to keep the FDA from knowing about the defibrillator problems, which are believed to have caused severe injuries and deaths.

This latest lawsuit started as whistleblower lawsuit brought by James Allen, a recipient of one of the defective implants. Under the qui tam provisions of the False Claims Act, Allen will receive $2.25 million of the settlement money.

Written by: Irvin Jackson

Senior Legal Journalist & Contributing Editor

Irvin Jackson is a senior investigative reporter at AboutLawsuits.com with more than 30 years of experience covering mass tort litigation, environmental policy, and consumer safety. He previously served as Associate Editor at Inside the EPA and contributes original reporting on product liability lawsuits, regulatory failures, and nationwide litigation trends.

Image Credit: |



0 Comments


Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

MORE TOP STORIES

A Texas mother is pursuing a lawsuit against Roblox and Discord, claiming the design of the apps allow sexual predators to access and groom young children.
Federal regulators are investigating whether Dupixent increases the risk of cutaneous T-cell lymphoma (CTCL), after more than 300 adverse event reports flagged cancer diagnoses among users. The FDA’s review comes as lawsuits are being pursued nationwide, alleging Sanofi and Regeneron failed to warn that the blockbuster eczema drug could either trigger or mask the rare blood cancer.